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Abstract: The identification and cloning of the vanilloid receptor 1 (TRPV1) represented a significant step for the
understanding of the molecular mechanisms underlying the transduction of noxious chemical and thermal stimuli by
peripheral nociceptors. TRPV1 is a non-selective cation channel gated by noxious heat, vanilloids and extracellular
protons. TRPV1 channel activity is remarkably potentiated by pro-inflammatory agents, a phenomenon that is thought to
underlie the peripheral sensitisation of nociceptors that leads to thermal hyperalgesia. Cumulative evidence is building a
strong case for the involvement of this receptor in the etiology of both peripheral and visceral inflammatory pain, such as
inflammatory bowel disease, bladder inflammation and cancer pain. The validation of TRPV1 receptor as a key
therapeutic target for pain management has thrust intensive drug discovery programs aimed at developing orally active
antagonists of the receptor protein. Nonetheless, the real challenge of these drug discovery platforms is to develop
antagonists that preserve the physiological activity of TRPV1 receptors while correcting over-active channels. This is a
condition to ensure normal pro-prioceptive and nociceptive responses that represent a safety mechanism to prevent tissue
injury. Recent and exciting advances in the function, dysfunction and modulation of this receptor will be the focus of this
review.
THE TRP RECEPTOR SUPERFAMILY
The Transient Receptor Potential (TRP) mammalian gene
superfamily consists of 28 different gene products encoding
non-selective cation channels that play a wide diversity
of physiological functions [24,79]. These channels are
considered molecular gateways in sensory systems, since
several of these channels transduce chemical and physical
stimuli into neuronal activity, i.e. action potentials. Thus,
TRP channels have emerged as major transducers of
chemically and physically evoked sensations.
Based upon their sequence homology, mammalian TRP
channels are divided into six subfamilies, namely TRPC,
TRPV, TRPP, TRPM, TRPA and TRPML [24,79,82]. An
additional family, TRPN, has been described in Drosophila.
These proteins have a common topology of six trans-
membrane segments (S1-S6) with a pore region between the
fifth and sixth segment, and cytoplasmic N- and C-termini.
TRPV and TRPC contain two-to-four ankyrin domains that
are thought to interact with the cytoskeleton, as well as with
other cytosolic proteins [24]. TRP proteins are remarkable
channels because of the diversity of their activation
mechanisms, cation selectivity and biological function. Some
members are activated through the phospholipase C-inositol
trisphosphate pathway, although the specific mechanism of
activation is still elusive [24,77]. Others, such as some
TRPV members, are ionotropic receptors activated by
chemical and physical stimuli [24,61]. The molecular
diversity of TRP proteins correlates with their wide number
of biological functions, ranging from fertility to vision, taste,
olfaction, osmo/mechanosensation, and nociception [61,77,
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79]. Therefore, TRP channels constitute a family of sensory
receptors.
THE TRPV1 CHANNEL
Among the TRP channel superfamily, TRPV1, TRPV2,
TRPV3, TRPV4, TRPM8 and TRPA1 are thermoreceptors
[80]. These receptors are designed to detect a wide range of
temperatures from hot (TRPV1 and TRPV2) and cold
(TRPA1) noxious temperatures to innocuous thermal stimuli
(TRPV3, TRPV4 and TRPM8) [24,80]. In addition, these
channels are activated by chemical agents such as capsaicin
(TRPV1), menthol (TRPM8), camphor (TRPV3) and mustard
(TRPA1) [19,60,74,81,80,100]. Furthermore, TRPV1 is also
gated by protons and endocannabinoids [19,61]. Notably, the
physiological properties of the receptor have signalled it out
as a key thermosensory transducer in the nervous system
[19,80]. In support of this tenet, analysis of vanilloid
receptor null mice has substantiated the involvement of this
channel in pain sensation [18,30].
At the molecular level, TRPV1 is a calcium permeable
non-selective cation channel. The functional receptor is a
tetrameric membrane protein with four identical subunits
assembled around a central aqueous pore, although hetero-
meric association with TRPV3 has been reported [98].
Structurally, each TRPV1 subunit protein shows a membrane
domain composed of six transmembrane segments (S1-S6),
with an amphipathic region between the fifth and sixth
segment that forms the channel conductive pore. This region
contains glutamic acids that are involved in the pH-
dependent gating of the receptor [19]. The protein also has a
cytoplasmic N- and C-termini (Fig. 1). In the N-terminus,
TRPV1 channels exhibit three ankyrin domains that mediate
protein-protein interactions with cytosolic proteins, and
show consensus sequences for protein kinases. The protein
displays a cytosolic C-terminus domain containing phospho-
inositide, and calmodulin binding (CAM) domains, as well
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as phosphorylation sites [24]. In addition, the C-end has a
TRP-like motif that functions as an association domain of
receptor subunits [39].
TRPV1 is an integrator of noxious stimuli that gates in
response to heat ( 42ºC), vanilloids, protons, and pro-
algesic substances [19,61]. Temperature sensing seems
related to voltage dependent gating, as evidenced by the shift
in TRPV1 voltage-dependent activation in response to
changes in temperature [111]. Chemical activators of TRPV1
channels can be grouped into those agents that directly gate
the channel, and those that allosterically modulate the
protein by post-translational modifications. Furthermore,
agonists of the receptor act as gating modifiers reducing the
temperature threshold of the channel gating [111]. Although
TRPV1 is a temperature-gated channel with a temperature
threshold of activation of 42ºC, it was recently shown that
TRPV1 may not be required for the detection of noxious heat
in intact C-fiber afferents [117]. However, the channel
becomes a pivotal heat sensor under pathological/
inflammatory states as concluded from genetic and pharma-
cological TRPV1 knock-out studies [18,30,38]. The receptor
has two abundant single nucleotide polymorphisms that
produce amino acid substitutions, one in codon 315 (Met
315
Ile) at the N-terminus domain, and the other at amino acid
585 (Ile
585
 Val) located in the fifth transmembrane segment.
Interestingly, gender, ethnicity and temperament seem to
contribute to individual variation in thermal and cold pain
sensitivity by interactions in part with these TRPV1 single
nucleotide polymorphisms [66].
A large body of evidence indicates that post-translational
modification of TRPV1 increases the channel activity of the
receptor [11,32]. Indeed, TRPV1 has several consensus
sequences for protein kinases A (PKA), C (PKC), calmodulin
kinase II (CAMKII) and the tyrosine specific kinase Src
(Fig. 1). PKA phosphorylation potentiates TRPV1 responses
by reducing agonist-induced desensitisation. Desensitisation
of the receptor depends on the presence of extracellular Ca
2+
,
and it is characterised by a profound run-down of its channel
activity upon repetitive agonist stimulation. PKA exerts its
action through partial rescue of desensitised receptors by
direct phosphorylation of amino acids S116 and T370 at the
N-terminus domain. Similarly, CaMKII-mediated phospho-
rylation, along with calcineurin-induced dephosphorylation
of the receptor, notably contributes to determine its
activation and desensitisation state [63,78]. Likewise, in
colonic dorsal root ganglion neurons, the channel activity of
TRPV1 is enhanced by tyrosine phosphorylation with the
nonreceptor tyrosine kinase Src [58]. Tyrosine phospho-
rylation of the protein may underlie in part to the IL-1-
induced potentiation of heat-activated currents in rat sensory
neurons [86].
PKC-dependent phosphorylation of TRPV1 can be
primarily induced either by extracellular ATP released from
injured cells, IL-1, proteases, neurotrophins and bradykinin
[86,102,110]. In vitro studies have identified S502, T704 and
S800 as PKC phosphorylation sites (Fig. 1). Different PKC
isoforms have been involved in TRPV1 sensitisation. For
instance, phorbol esters primarily activate PKC  [87],
although they can also act as a direct ligands of TRPV1
[10,83]. In contrast, stimulation of bradykinin B1 and B2
receptors leads to PKC activation [20,102]. More recently,
PKC, a kinase related to, but distinct of the PKC family has
been shown to phosphorylate and sensitise both hetero-
logously expressed and native TRPV1 channels [115]. PKC
phosphorylation of the vanilloid receptor notably enhances
its responsiveness by augmenting the channel open
probability [93]. Akin to vanilloids and pH, TRPV1 phospho-
rylation by PKC decreases the receptor heat threshold, thus
leading to activation of the channel at body temperature. In
addition, PKC activation promotes the rapid recruitment of
vesicular receptors to the cell surface [83]. The occurrence of
both events provides a molecular mechanism for the pain
experienced in response to a warm stimulus, such as
showering sunburnt skin.
EXPRESSION OF TRPV1 CHANNELS
In situ hybridisation, immunocytochemical analysis, and
drug binding assays have shown TRPV1 expression in 50%
of dorsal root and trigeminal ganglion neurons, in dorsal
Fig. (1). Proposed model of the topology of TRPV1 subunits. Each subunit consists of six putative transmembrane segments and intracellular
N- and C- domains. Functional regulatory domains of the receptors and phosphorylation sites are indicated. The capsaicin binding site is
labelled withe the chili icon.
Physiology and Pharmacology of the Vanilloid Receptor Current Neuropharmacology, 2006, Vol. 4, No. 1 3
horn of spinal cord and caudal nucleus of spinal trigeminal
complex [19,107]. The majority of TRPV1 positive neurons
also colocalise with the nerve growth factor (NGF) receptor
trkA , the lectin IB4, and the neuropeptides involved in
nociceptive transmission such as substance P (SP) and
calcitonin gene related peptide (CGRP) [19,61]. Vanilloid
sensitive nociceptors are peptidergic, small diameter neurons
that give rise to unmyelinated C fibers, although some A
fibers are responsive to vanilloid derivatives [49]. Somatic
and visceral primary afferents express TRPV1 at both the
spinal and peripheral terminals. Furthermore, TRPV1
expression has been reported in vagal afferents in jugular and
nodose ganglion neurons [54,84].
In addition to a subset of nociceptors, TRPV1 is present
in neurons of the central nervous system and non-neuronal
cells. For instance, TRPV1 mRNA or protein is widely
expressed in brain regions such as the olfactory nuclei,
cerebral cortex, dentate gyrus, central amygdala, striatum,
centromedian and paraventricular thalamic nuclei, hypotha-
lamus, substantia nigra, reticular formation, locus coeruleus,
inferior olive and cerebellar cortex [see 84 and references
therein]. The role of TRPV1 in the central nervous system is
still elusive, although it may mediate endovanilloid signalling
promoting the release of excitatory neurotransmitter such as
L-glutamate, noradrenaline and dopamine [71,72].
In the skin, TRPV1 positive cells have been found in the
dermis and epidermis [46], primarily in Meissner corpuscles
and keratinocytes [56,88]. Moreover, this receptor is also
expressed in mast cells, where its activation could release
mast cell pro-algesic mediators that bind to histamine and
proteinase-activated receptors on sensory terminals [99].
More recently, functional TRPV1 channels were found in the
human hair follicle [15]. Activation of this receptor in
cultured keratinocytes inhibited cellular proliferation, induced
apoptosis, up regulated known endogenous hair growth
inhibitors, and down regulated hair growth promoters. Thus,
these results suggest an important role of TRPV1 in
epithelial growth disorders [15].
It is also worth mentioning that TRPV1 receptors appear
to be highly expressed in visceral afferents [53], and are
present in the gastrointestinal (GI) tract within the myenteric
and submucous plexus and some enteric intrinsic neurons
[116]. Although capsaicin does not desensitise gastric
epithelial cells, activation of TRPV1 expressing primary
afferents has been shown to thicken the protective barrier in
the stomach and duodenum [84], and sensitisation of this
receptor plays a role in GI inflammation and function [41].
In pathological conditions, TRPV1 has been implicated in
the hypermotility of the GI tract in abdominal pain
associated to functional bowel disorders, and in the
neurogenic component of pancreatitis [1,49].
TRPV1 expression is also prominent in other tissues. In
the urinary bladder, functional channels are expressed in the
uroepithelium in both the superficial and basal layers [4],
where they are implicated in the development of the
micturition reflex in both normal and pathological conditions
[12]. In the lungs, capsaicin stimulates airway specific C-
fibers and may play a role in the generation of non-
productive cough [65]. Neurogenic inflammation of mucosal
nociceptors also seems to be a key factor in the pathogenesis
of asthma [44]. Under normal conditions, these fibers do not
express SP but begin to produce it after allergic
inflammation and viral infection [17,51]. In the vascular
system, TRPV1-expressing fibers accompany blood vessels
in all layers of the viscera. These receptors appear involved
in Bayliss myogenic constriction which leads to
hypertension [97]. Furthermore, TRPV1 seems to contribute
to myocardial protection by releasing CGRP and nitric oxide
from capsaicin-sensitive afferents in the ischemic heart
[101]. Another tissue that expresses TRPV1 channels is the
inner ear, where the protein is present in inner and outer hair
cells, inner and outer pillar cells, Hensen cells and satellite
cells [8,121]. These channels appear to be involved in
hearing, as evidenced by the vanilloid-induced alteration of
cochlear sensitivity [104].
Taken together, all these findings illustrate that TRPV1
channels are widely expressed in neuronal and non-neuronal
cells of both endodermal and mesodermal origin, and
suggest that the receptor is involved in diverse physiological
functions. These include thermosensory transduction, as well
as chemical signalling presumably mediated by endovanilloid
compounds. In addition, they hint that dysfunction of the
channel may underlie the etiology of pathological sensory
transduction such as that occurring in inflammation. Taken
together, all these observations underscore the notion that
TRPV1 is a widely expressed protein whose function may be
critical for diverse physiological conditions.
TRPV1 A THERAPEUTIC TARGET FOR PAIN
MANAGEMENT
The pivotal role of TRPV1 in physiology has suggested a
contribution of the channel to the mechanism of diverse
human diseases. In particular, cumulative evidence is
substantiating the tenet that nociceptor sensitisation by
inflammatory agents is primarily achieved by TRPV1. This
receptor is the endpoint target of intracellular signalling
pathways triggered by inflammatory mediators that lead to
potentiation of its channel activity which, in turn, promotes
the hyperexcitability of nociceptors. Enhancement of TRPV1
function by pro-algesic agents may be accomplished either
by direct activation of the channel or by its post-translational
modification mediated by intracellular metabolic cascades
[24,80]. Direct activation of TRPV1 responses has been
reported for lipid mediators such as arachidonic acid
metabolites including anandamide, N-arachidonyl-dopamine
(NADA), N-oleyldopamine and, 12-(hyperoxy)eicosatet-
renoic acid (12-HPETE). These compounds act as weak
agonists, but notably increase TRPV1-mediated [Ca
2+
]i in
both heterologous expression systems, and in primary
sensory neurons [22,50,52]. In addition, the acidosis that
develops in inflamed tissues is also a direct activator of the
TRPV1 channel activity [19]. The potency and efficacy of
each singular mediator is quite low but in inflammatory
conditions, several of these modulators are simultaneously
released and act synergistically. Noteworthy, most of these
TRPV1 ligands act by reducing the heat threshold of channel
activation from 42ºC to body temperature (35ºC) [11].
Therefore, direct gating of TRPV1 responses by inflammatory
agents acting as channel agonists notably increases the
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excitability of nociceptors resulting in a hyperalgesic
condition. In addition, the TRPV1-mediated [Ca
2+
]i rise, in
turn, triggers the release of pro-inflammatory agents at
peripheral terminals, thus further increasing the excitability
of the nociceptors. This feedback circuit notably contributes
to enhance the hypersensitivity of inflamed tissue.
Activation of intracellular protein networks during
inflammation results in TRPV1 phosphorylation [11], release
of tonically-inhibited receptors [23], and an increment of the
surface expression of functional channels [83], all being
major events underlying the nociceptor activation and
sensitisation that leads to hyperalgesia. Indeed, TRPV1
expression is upregulated in tissue samples from patients
with inflammatory bowel disease and Crohn´s disease [118],
and also in patients with rectal hypersensitivity [21], as well
as those affected of vulvodynia [108]. Thus, TRPV1
receptors are strong candidates for an important role in the
sensitisation of primary afferents after injury or inflammation.
The involvement of TRPV1 in heat hyperalgesia is under-
scored by the reduced thermal hypersensitivity of mice
lacking TRPV1 [18,30]. Similarly, non-competitive anta-
gonists of the TRPV1 channel notably attenuate the heat
hyperalgesia triggered by inflammation in vivo [38]. The
important contribution of TRPV1 receptor to the onset and
maintenance of neurogenic inflammation has validated it as a
therapeutic target for inflammatory pain management.
In addition to the contribution of the vanilloid receptor as
a target of the neurogenic inflammation underlying different
diseases, TRPV1 is gaining interest for the treatment of
neuropathic, postoperative and chronic pain and, recently,
for the therapy of epithelial disorders. Thus, for instance,
topical capsaicin or resiniferotoxin have been used in
postherpetic neuralgia, diabetic neuropathy, postmastectomy
pain and arthritis [64,103]. Recently, TRPV1 has been
clearly validated as a key target for management of chronic
pain in bone cancer [42]. As a result, the development of
specific TRPV1 antagonists is a central focus of current drug
discovery programs.
PHARMACOLOGY OF TRPV1 RECEPTORS
The TRPV1 receptor is a molecular entity with diverse
drug binding sites. Structure-function studies have unmasked
the molecular determinants of the capsaicin binding site in
an intracellular domain of the receptor (Fig. 1) [40,59], and
those involved in the interaction with the non-competitive
antagonist ruthenium red at the extracellular vestibule of the
pore domain [37]. The existence of these binding sites has
prompted the discovery of novel vanilloid-like agonists, as
well as competitive and non-competitive antagonists with the
hope that they will be of clinical use to treat human TRPV1
receptor dysfunction. Further summarized are the efforts
undertaken to develop these three classes of TRPV1
modulators.
TRPV1 AGONISTS
Agonists are molecules that directly gate the channel by a
mechanism that involves the reduction of the heat threshold
of activation. Prolonged exposure of the receptor to the
agonist in the presence of Ca
2+
 induces channel closure by
desensitisation and tachyphylaxia [103], by a mechanism
that involves phosphorylation of a key residue at the C-
terminus of the protein [11]. Agonist-induced desensitisation
is thought to underlie the analgesic activity of capsaicin.
However, capsaicin analgesia may also arise from selective
deletion of TRPV1-expressing nociceptors due to the Ca
2+
overload that may induce the ligand [64]. Thus, high-affinity
agonists that promote receptor tachyphylaxia and/or noci-
ceptor ablation could be used as efficacious pain relievers.
The identification of several natural products that act as
TRPV1 ligands prompted the use of these molecules as
pharmacological tools to study this receptor even before its
molecular identity was known. In addition, these studies
opened different medicinal chemistry programs based on
structure-activity relationships (SAR) directed to improve
the therapeutic profile of the initial hits.
Vanilloids are the best known kind of TRPV1 agonists.
Capsaicin (1, Fig. 2) is the representative example of this
family. This molecule bears the 4-hydroxy-3-methoxybenzyl
moiety characteristic for homovanillin derivatives, an amide
linker and a lipophilic region. The homovanillyl motif and
the amide linker contain polar groups capable of forming
hydrogen bonds. The SAR studies performed on capsaicin
analoges suggest that these polar moieties are essential for
exciting sensory neurons. In contrast, the hydrophobic
region, with an optimal chain length of 8-15 carbon atoms,
would interact with a hydrophobic region in the receptor.
Unlike other ligand-gated channels that produce fast synaptic
transmission, vanilloids show a slow activation kinetics, in
part because their binding site is located in the intracellular
portion of the receptor (Fig. 1) [31,40,59,62]. Indeed, a
cytosolic region spanning the third transmembrane domain
in TRPV1 appears to be essential for capsaicin binding,
presumably through hydrophobic interactions with the
vanilloid carbon chain [40,59]. The structural determinants
involved in capsaicin binding are being unravelled and
molecular models for the vanilloid site have been proposed
which, upon refinement, may facilitate the design of agonists
with higher therapeutic index [40].
There are other known classes of naturally occurring
vanilloids, such as Resiniferatoxin (RTX, 2), a compound
isolated from Euphorbia resinifera, that exhibits a TRPV1
agonistic activity much more potently than capsaicin (IC50=
10 pM). As shown in Fig. 2 , RTX is a rather complex
molecule and the pharmacophoric groups have not been
clearly defined yet. SAR studies suggest that the homo-
vanillic moiety of RTX, the C3-keto group and the orthoester
phenyl moiety in ring C are essential structural elements for
eliciting its extremely high potency desensitising TRPV1
channel activity. As a consequence, RTX is being developed
as a sensory neuron desensitising agent for the treatment of
urinary urge incontinence and pain associated with diabetic
neuropathy [105], two human pathologies mediated by
TRPV1 dysfunction. In spite of these results, the limited
availability of RTX from natural sources and its difficult
chemical synthesis hamper its therapeutic use.
The efficacy of both capsaicin and RTX for treating
overactive bladder and neuropathic pain has stimulated the
efforts for identifying orally active TRPV1 agonists. A major
shortcoming for the therapeutic use of capsaicin and related
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vanilloids is the burning sensation and irritation that they
provoke. In addition, the phorboid group of RTX has raised
concerns of tumorigenicity. The development of more
potent, orally active vanilloid derivatives (See Fig. 2) such as
SDZ-249482 (3 , Fig. 2), olvanil (4, Procter and Gamble),
SDZ-249665 (5 , Novartis) or the complex capsaicin
analogue reported by Takeda (6) did not fully circumvent the
discomfort of the side effects derived from irritation.
Recently, homoallylic hydroxylation and further acylation of
the fatty acyl chain of olvanil has led to the identification of
phenylacetylrinvanil (7b, Fig. 2), an ultra-potent capsaicinoid
(EC50=11 pM) that reduces bladder detrusor overactivity in
vivo in a rat model of urinary incontinence with a potency
similar to resiniferatoxin [3].
In parallel to the identification of vanilloid-like agonists,
the development of new formulations for capsaicin such as
dermal patches (NGX-4010 from NeurogesX) or localised
injections (ALGRX-4975 by AlgoRx) are currently evaluated
as analgesic strategies. The vanilloid analog DA-5018 (8,
Dong A Pharmaceuticals) is also under development as a
topical analgesic. Thus far, clinical data gathered indicate
that the use of TRPV1 agonists as analgesics has clear cut
advantages such as long lasting effects, broad mechanism of
action, and high potency for the case of RTX. However,
these molecules exhibit side effects such as pungency and
pain that limit their clinical application. Therefore, the
identification of non-pungent vanilloid-like drugs that induce
a long-lasting desensitisation of the receptor will be of great
clinical value.
Fig. (2). Structures of a selection of natural and synthetic TRPV1 agonists.
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There is good evidence on the occurrence of endogenous
vanilloid receptor agonists, coined with the term endo-
vanilloids, and that these agents modulate the sensitivity of
TRPV1 channels to thermal stimuli [109]. For instance, it
has been described that a polyunsaturated compound derived
from arachidonic acid, anandamide (9, Fig. 3) activates both
native and recombinant TRPV1 receptors [122]. The
structure of the molecule does not give evidence that it is a
vanilloid analog. This fact caused some confusion about the
term “vanilloid” depending on whether it is used chemically
or pharmacologically. Moreover, anandamide is also
considered as an endocannabinoid, since it activates
cannabinoid (CB) receptors CB1 and CB2 at concentrations
lower than those required to gate TRPV1 [122]. Similarly,
several eicosanoids, particularly those derived from the
enzymatic action of 5-lipoxygenase or 12-lipoxygenase, are
capable of activating rat TRPV1. In particular, 12-HPETE
(10 , Fig. 3) and leukotriene B4 (11 , LTB4, Fig. 3) have
exhibited the most potent agonistic activity [50]. It is
believed that eicosanoids function as intracellular vanilloids
of TRPV1 receptors in the cells where they are synthesised.
Recently, NADA (12, Fig. 3) has been identified as a brain
endovanilloid [52]. NADA is an endogenous anandamide
analog several times more potent than anandamide on
TRPV1, although it still activates CB1 receptors.
Another related approach to modulate TRPV1 signalling
is the identification of the so-called hybrid cannabinoids/
TRPV1 ligands. Since TRPV1 colocalises with CB1
receptors in brain, and both proteins have overlapping ligand
recognition properties, it is possible to conceive compounds
capable of activating both receptor types simultaneously
even by different mechanisms. Arvanil (N-[3’-methoxy-4’-
hydroxybenzyl]arachidonamide, 13, Fig. 3) is one of these
agents. Arvanil has affinity for CB1 receptors and activates
TRPV1 receptors more potently than capsaicin or anandamide
[75]. This compound is an antiproliferative agent for human
breast cancer cells sensitive to both CB1 and TRPV1
receptor antagonists, as well as a spinal analgesic and, a
relaxant of mouse vas deferens. Similarly, arachidonyl
ethanolamine, an endogenous cannabinoid that also acts on
the TRPV1 channel, induced strong apoptosis of uterine
cancer cells that aberrantly express the vanilloid receptor
[24]. Accordingly, it is of great interest for the future
development of improved hybrid CB1/TRPV1 agonists.
TRPV1 ANTAGONISTS
Intense efforts have been carried out to design TRPV1
competitive and non-competitive antagonists [91,106]. The
competitive antagonists bind to the agonist binding site, and
lock the channel in the closed, nonconductive state. In
contrast, non-competitive antagonists interact with additional
binding sites on the receptor structure preventing receptor
opening by the agonist or blocking its aqueous pore [91].
Non-competitive antagonists acting as open channel blockers
are therapeutically attractive because they preferentially
recognise the population of over-activated TRPV1 channels
with a marginal recognition of physiologically working
receptors. Thus, this kind of drugs target pathologically-
activated receptors, which can reduce the potential unwanted
side effects.
TRPV1 COMPETITIVE ANTAGONISTS
The first competitive TRPV1 antagonist, capsazepine
(14, Fig. 4), was identified by Sandoz (now Novartis) and
Fig. (3). Structures of TRPV1 endogenous ligands and hybrid canabinoid-TRPV1 modulators.
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was used as a valuable pharmacological tool to understand
the capsaicin-induced effects on nociceptors in vivo before
the TRPV1 channel was cloned. This compound can be
considered as a conformationally-restricted capsaicin analog
bearing a thiourea moiety instead of the urea present in
capsaicin. The propylidene linker of the seven-membered
ring forces the dihydroxylated aromatic moiety to adopt an
orthogonal orientation with respect to the thiourea bond.
This steric constraint was considered essential for eliciting
the receptor antagonistic activity, although development
of acyclic vanilloid-based derivatives lacking this spatial
disposition and eliciting higher inhibitory potency than
capsazepine questioned the relevance of this SAR statement.
Pharmacological studies showed that capsazepine exhibited
low metabolic stability and poor pharmacokinetic properties
in rodents, thus preventing its clinical development.
Furthermore, pre-clinical studies on animal models of pain
have provided conflicting results. For instance, the
compound shows poor anti-inflammatory and analgesic
activity in rats, although it remarkably attenuates thermal
and mechanical hyperalgesia in guinea pigs [113].
Fig. (4). A selection of TRPV1 competitive antagonists.
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The discovery that the introduction of an iodine atom on
the vanillyl moiety of RTX agonist modulates its
pharmacological activity depending on the position of the
halogen ended up with the identification of 5-iodoRTX (15,
Fig. 4) as a potent antagonist of TRPV1 (IC50 = 3.9 nM)
[73,112]. This compound produced analgesic activity in vivo
and it is currently in clinical studies. Similar to RTX, a major
drawback of compound 15 is its complex chemical structure
and, the cost of its synthesis from RTX itself. In addition, 5-
iodoRTX exhibits low oral bioavailability probably due to its
poor pharmacokinetic properties. Nevertheless, the discovery
of compound 15 stimulated the SAR studies on the halo-
genation of the vanillyl moiety present in simple capsaicin
derivatives. For instance, taking nonivamide as a model
(16a, Fig. 4), the substitution at C-6 afforded more potent
inhibitors than at C-5 and the inhibitory potency correlated
with the size of the halogen (I > Br > Cl) [2]. The most
potent derivative identified was that bearing the iodine atom
at C-6 (16b). Similarly, iodination of phenylacetylrinvanil
(7b) produced a potent TRPV1 antagonist (IC50 = 0.8 nM)
[3]. These results showed that halogenation could be an
appropriate strategy for reversing the activity of vanilloids.
This observation, together with the aim of synthesising
simpler derivatives of RTX that preserve the inhibitory
potency of the parent compound, would constitute an
attractive field for developing orally active, competitive
TRPV1 antagonists with improved pharmaceutical profiles
for clinical use.
A related family of capsaicin analogues was developed
by Neurogen through the formal amidation of the homo-
vanillylamino moiety with different 4-(-pyridyl)piperidine-
1-acyl residues. The urea 17 (Fig. 4) is a representative
example of this family [6]. The presence of an amino moiety
at the hydrophobic region of the capsacinoid appeared to be
crucial for obtaining a potent inhibitor that was, at the same
time, a highly improved drug lead in terms of hydrophilicity.
This observation was also important to recognise that the C-
region of capsaicin should be considered as a domain that
plays a key role in the interaction with the receptor. Another
piperazinyl urea (BCTC, 18) was reported by Purdue-
Pharma to be more selective than capsazepine against a wide
variety of enzymes and channels. This compound exhibited
in vivo oral activity in animal models of inflammatory and
neuropathic pain [92]. Less conformationally-restricted
analogs of BCTC such as compounds 19 and 20, along with
the recently reported pyrrolidine urea 21 (Fig. 4), also elicit a
good antagonistic TRPV1 potency maintaining the receptor
selectivity. The ongoing pre-clinical characterization of these
compounds will uncover whether they have a higher
therapeutic index than BCTC [94]. It is worth noting that
most of these molecules were identified from the screening
of chemical combinatorial libraries, thus showing the
usefulness of this strategy in drug discovery programs.
Structurally connected to capsaicin related compounds,
thiourea 22a (Fig. 4) elicited a potent agonist activity (Ki <
10 nM). Interestingly, the presence of fluorine at C-3’ and
the methanesulfonamido moiety at C-4’, replacing the
methoxy and hydroxy groups, respectively, afforded
compound 22b, a molecule exhibiting an antagonistic TRPV1
activity [68]. Further modification of these derivatives, now
at the lipophilic region, led AmorePacific to obtain
optimized compound 23, bearing a tert-butyl group at the
aromatic ring [114].
The continuous efforts to improve the pharmacological
properties of TRPV1 antagonists have resulted in the
development of novel templates (See Fig. 5). In this regard,
several non-symmetric ureas have been reported by Janssen
[25], Abbott [69] and Merck [16], where the 5-
aminoisoquinoline moiety appears as a common feature (cf.
24-26). Alternatively, Bayer has reported the 4-aminoindole
27 [119] and the hydroxylated tetrahydronaphthalene 28
[119] urea derivatives. All these compounds show an
inhibitory potency  10 nM. Taken together, these results
emphasise the relevance for antagonistic activity of a
functionalised lipophilic moiety, preferentially with a basic
group, for interacting with the capsaicin binding site on
TRPV1.
The replacement of the urea moiety by other isosteric
groups has also been explored. Euroceltique reported
Fig. (5). TRPV1 antagonists based on novel templates.
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compound 29 (Fig. 5), based on the piperidine templates
reported earlier (cf. 17 and 18), where the cyanoguanidine
group substituted the urea [67]. A further alternative to
the ureas are the amides explored by GlaxoSmithKline.
Compound SB-366791 (29) exhibits a potent competitive
antagonistic activity (IC50 5 nM) in both the human and rat
TRPV1 receptors and it shows a better selectivity profile
than capsazepine [45]. Further studies led to the
identification of compound 30, which also exhibits a good in
vitro inhibitory activity. In addition, this molecule is readily
amenable for structural optimisation, as shown by the
synthesis of the tetrahydroquinoline 31.
A further approach for the development of TRPV1
efficient antagonists is characterised by those derivatives
lacking the urea, thiourea or amide groups (see Fig. 6).
Compounds 32-37 are examples of this approach that have
been reported from different companies. The pyridine
derivative 32  [28], the quinazolin-4-one 33  [29] from
Novartis and the quinazoline-4-ylamine 34 [7] from Neurogen
were the first compounds disclosed. A second derivative
from Neurogen 35 [8] containing a residue of propionic acid
(or phosphate or phosphonate) attached to the quinazoline
moiety followed. In addition, two more derivatives,
compounds 36 [14] and 37 [9], from Amgen containing
heterocyclic moieties at the central regions have been also
reported. More recently, the group of Abbott has described a
collection of urea derivatives from which an analogue of
compound 24 displaying a trifluoromethyl substituent at the
meta position of the phenyl residue exhibited an IC50 = 4
nM, a 46% of oral bioavailability and, in vivo analgesic
activity in animal models of visceral and inflammatory pain
[43]. Overall, the strength of the heterocyclic
pharmacophores studied was 5-isoquinoline > 8-quinoline =
8-quinazoline > 8-isoquinoline  cinnoline  phtalazine 
quinoxaline  5-quinoline. Lastly, a group from Amgen has
published a study on different analogs based on its
acrylamide antagonist 38 . From the N-aryl cinnamides
synthesised, optimised compounds 39 and 40 exhibited high
antagonist potency and good oral bioavailability in rats, as
well as a favourable pharmacokinetic profile [33]. Although
much of these compounds display in vivo anti-inflammatory
and analgesic activity in animal models, further studies are
required to assess the efficacy in the clinic. These exciting
results are eagerly awaited.
Collectively, all these findings illustrate that development
of potent competitive vanilloid antagonists of TRPV1
activity is a hot field of current neuropharmacology.
Analysis of the structures shows the use of scaffolds that
preserve little resemblance to the original vanilloid group or
even to the capsacinoid family. On the other hand, even in
the absence of detailed knowledge of the topology of the
TRPV1 receptor, the wide variety of active structures
reported thus far provide a significant database for initiating
molecular modelling and SAR approaches aimed at the
Fig. (6). Novel TRPV1 antagonists lacking the urea or thiourea groups (31-36), or based on the N-arylcinnamide moiety (37-39).
N N
H
NH
tBu
O
S
Cl
N
NH
iPr
O
Cl
N
N
HN
CF3
N
CF3
N
N
HN
CF3
N
CF3
OH
O X N
H
N
R1
R
N
H
N
N N
N
Cl
F3C
32 33 34
35 36(X=C,N) 37
O
O
N
H
O
38
N N
H
N
NO
CF3
O
N N
H
N
NO
CF339 40
10 Current Neuropharmacology, 2006, Vol. 4, No. 1 Messeguer et al.
identification of the pharmacophoric features required for
orally active, potent antagonistic activity. These studies are
also necessary to clarify whether the above structural variety
is due to the interaction with sames of different drug binding
sites on the receptor.
TRPV1 NON-COMPETITIVE ANTAGONISTS
The first non-competitive TRPV1 antagonist, and the
only molecule available for several years as vanilloid
receptor blocker was the trinuclear polyamine complex,
Ruthenium red (41, Fig. 7). This compound binds to the pore
region of the channel with high potency (IC50, 100 nM) and
weak voltage dependency by a mechanism that involves
interaction with negatively-charged residues present at the
outer vestibule of the ionic pore [37]. The poor receptor
selectivity of this compound seems to underlie its
proconvulsive activity in animal models that preclude the
clinical development. Arginine-rich hexapeptides such as
RRRRWW-NH2 block recombinant TRPV1 channels
expressed in Xenopus oocytes in a non-competitive manner
with submicromolar potency (42, Fig. 7) [90]. However, it
was later suggested that these derivatives might partially act
as competitive antagonists [48]. Nonetheless, similar to
ruthenium red, their lack of receptor selectivity resulted in
severe side effects and toxicity, thus preventing further their
development as analgesics.
A parallel effort was carried out to evaluate poly-
methylene tetraamines as TRPV1 channel blockers [76].
These studies identified methoctramine (4 3 ) as a non-
competitive capsaicin antagonist with an IC50 of 2 M, and
notable voltage-dependent blockade (Fig. 7). This molecule
Fig. (7). TRPV1 non-competitive antagonists.
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antagonised native TRPV1 receptors in dorsal root ganglion
neurons activated by either capsaicin or protons. Therefore,
the inhibitory activity of methoctramine analogs has
provided a new pharmacophoric scaffold for non-competitive
antagonists of TRPV1. Thus far, the lack of receptor
selectivity has restrained the use of these compounds in vivo.
The first small organic molecules identified as non-
competitive TRPV1 emerged from the screening of a
peptidomimetic combinatorial library. N-Alkylglycines (also
known as peptoids), constitute a class of compounds of
synthetic origin that exhibit interesting biological properties
derived from their structural features, i.e, the absence of CO-
NH bonds and then of the hydrogen bond interactions that
they induce, an improved stability against proteases and a
high degree of conformational freedom. In addition, the
structural simplicity of peptoids makes these peptidomimetic
compounds amenable to structural manipulation, thus
facilitating the optimisation of identified hits for improving
their drug-like properties [47]. This is important if it is
considered that the high conformational mobility of these
molecules can generate selectivity problems due to undesired
interactions with non-target receptors.
The screening of the library of trimers of N-alkylglycines
led to the identification of two compounds referred to as
DD161515 (44) and DD191515 (45) that preferentially block
TRPV1 channel activity with micromolar potency and
moderate voltage-dependency (Fig 7) [38]. These peptoids
appear to recognise a receptor site different from that of
capsaicin. Intraperitoneal administration of both trialkyl-
glycines into mice significantly attenuated pain and
neurogenic inflammation induced by injection of capsaicin
into the hindpaws and, reduced thermal hyperlalgesia due to
mustard oil-evoked tissue irritation. In contrast, these
peptoids did not affect capsaicin triggered-mechanical hyper-
sensitivity [38]. These findings suggested that TRPV1 active
trialkylglycines may be developed into analgesics to treat
inflammatory pain. However, the in vivo doses required for
analgesic and anti-inflammatory activity were too high (25
mg/kg), thus preventing their development into useful drugs.
Therefore, the design of more potent, non-competitive
antagonists of TRPV1 is a yet unmet goal of drug discovery
platforms. Recent progress in this arena, along with
molecular modelling of the TRPV1 pore domain [35], is
providing this kind of compounds. For instance, by
combining the chemical features of arginine-rich peptides
and peptoid DD161515, a potent non-competitive antagonist
(H-Arg-15-15C, 46) of TRPV1 was discovered (Fig. 7) [34].
Compound H-Arg-15-15C blocked capsaicin-induced
TRPV1 activity with 10-fold higher potency than the original
peptoid DD161515, without compromising the receptor
selectivity. Noteworthy, at variance with the parental peptoids,
compound H-Arg-15-15C potently abrogated pH-activated
TRPV1 responses. As for DD161515, the blockade
mechanism was non-competitive acting as a channel blocker.
Thus, introduction of a strong positive charge in the
pharmacophore provided by peptoid DD161515 results in a
significant increase in the binding efficacy of the molecule to
the receptor. Noteworthy, compound 46 notably attenuated
the inflammatory discomfort exerted by intraplantar injection
of capsaicin. The i.p. dose required to produce analgesia was
10-fold lower than that of peptoid DD161515. In addition,
the compound showed activity on the Phase II of the
formalin model, although at doses relatively high, suggesting
a modest activity of the antagonist in neuropathic pain
models [96]. Indeed, H-Arg-1515C did not mitigate
mechanical allodynia in the partially ligated sciatic nerve
model of neuropathic pain. In contrast, 46  completely
reversed the complete Freund Adjuvant (CFA)-induced
thermal hyperalgesia at therapeutic doses (5 mg/kg, i.p.).
Collectively, these findings show that compound H-Arg-15-
15C is a potent non-competitive antagonist of the receptor
that exhibits notable anti-inflammatory and analgesic activity
in pre-clinical models of acute and chronic pain. However,
compound 46 displays limited oral and i.p. bioavailability in
vivo, presumably because of its lack of compliance with the
Lipinski rule of 5 [70]. Thus, chemical modification on the
H-Arg-15-15C structure will be necessary to increase its
therapeutic potential. All these results demonstrate that
TRPV1 antagonists that act on a site different from the
vanilloid binding site are also promising candidates for
analgesic/anti-inflammatory drug development.
THE TRPV1 RECEPTOR COMPLEX AS A THERA-
PEUTIC TARGET
Similar to other TRP channels, TRPV1 is arranged in
major molecular complexes establishing high order
signalling networks that notably determine the response to
external stimuli. These protein networks are in turn the target
of intracellular signaling pathways that modulate their
composition, structure and function. Thus, an emerging
notion is that ion channels are not isolated entities in cell
membranes but pivotal components of these macromolecular
assemblies. These complexes are composed of a plethora of
diverse polypeptides including scaffolding proteins,
receptors, enzymes and cytoskeletal proteins. The molecular
components of the TRPV1 complex identified thus far
include the high affinity neurotrophic receptor (TrkA),
phospholipase C (PLC), and calmodulin [85,95]. The
composition of these assemblies appears important for the
regulation of the receptor activity. Activation of trkA and
PLC, along with translocation of PKC, decrease the tonic
inhibition that phosphatidylinositol bisphosphate exerts on
TRPV1, thus promoting channel activity [23]. Similarly,
activation of PKA and CAMKII gives rise to a decrease in
Ca
2+
-induced receptor desensitisation and tachyphylaxia.
Cumulative evidence indicates that modulation of receptor
complexes underlie the TRPV1 potentiation by inflammatory
mediators.
A yeast-two hybrid screen of a rat brain library using the
N-terminus of TRPV1 as a bait identified two synaptic
vesicle proteins, Snapin and Synaptotagmin IX, as interacting
partners of TRPV1 [83]. Noteworthy, these proteins bind to
SNARE proteins and participate in neuronal exocytosis
[36,55], suggesting that surface delivery of TRPV1 channels
is a highly regulated, Ca
2+
-dependent exocytotic process.
Indeed, the interaction of both vesicular proteins with
TRPV1 appears temporal and seems not involved in the
formation of the molecular complexes at the cell surface.
However, these interactions are pivotal for the trafficking
and surface expression of TRPV1 channels. In support of
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this tenet, PKC-induced TRPV1 trafficking to the plasma
membrane was blocked by botulinum neurotoxins, thus
indicating that PKC- sensitisation of TRPV1 receptors is due
at least in part to the regulated exocytosis of channels located
in a reserve pool of cytosolic vesicles [83]. A recent
observation that botulinum neurotoxin attenuates heat
hyperalgesia substantiates this hypothesis [27], although
additional in vivo experiments are needed to determine the
precise role of receptor exocytosis to the onset and main-
tenance of neurogenic inflammation. Therefore, regulation of
TRPV1 surface density in nociceptor peripheral terminals
appears to be an important mechanism for both the
development and preservation of inflammatory hyperalgesia.
CFA-induced inflammation triggers an increased translation
and trafficking of TRPV1 channels to the peripheral
terminals [57]. These findings imply that modulation of
TRPV1 trafficking may be a therapeutic approach for pain
management. Accordingly, botulinomimetic compounds
such as small peptides that inhibit SNARE-dependent
exocytosis could be developed as anti-inflammatory and
analgesic compounds [13].
CONCLUSION
The recognition of the important role the TRPV1 in the
etiology of neurogenic inflammation and pain transduction
has thrust the development of down regulators of its channel
activity as analgesic drugs. Several of these compounds are
initiating clinical studies in humans and their results are
awaited. However, a note of caution must be sound because
of the pivotal and diverse physiological functions played by
the TRPV1 channel. Its widespread distribution in different
tissues should be taken into account since undiscriminate
pharmacological block of the receptor may lead to severe
side effects that may complicate the use of antagonists of
TRPV1 activity. Thus, the challenge of molecular
neuropharmacology would be to develop receptor-selective
drugs that preserve the physiological activity of TRPV1
while down regulating the function of overactive receptors.
This kind of compound would not compromise the normal
sensory signaling that is essential for survival.
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ABBREVIATIONS
TRPV1 = transient receptor potential vanilloid subunit 1
PKA = protein kinase A
PKC = protein kinase C
NGF = nerve growth factor
RTX = resiniferatoxin
SP = substance P
CGRP = calcitonin gene related peptide
NADA = N-arachidonyl-dopamine
SAR = structure-activity relationships
CFA = complete Freund adjuvant
CAMK = calmodulin kinase
PLC = phospholipase C
GI = gastrointestinal
TrkA = high affinity neurotrophic receptor.
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